Q-omics provides the consensus-scored CHEK2P3 profile across patient tissues and cancer cell-line models. CHEK2P3 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHEK2P3 is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, CHEK2P3 RNA expression shows 7,645 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UVM, KIRP, and COAD as cancer lineages where CHEK2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHEK2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHEK2P3 survival associations across molecular data types. CHEK2P3 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHEK2P3 RNA expression–survival associations across cancer types. High CHEK2P3 expression shows unfavorable associations in UVM, LIHC, THCA, OV and CESC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CHEK2P3 RNA expression.
This table summarizes CHEK2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CHEK2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHEK2P3 shows higher tumor expression in KIRP. The KIRP box plot shows higher CHEK2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .044).
This table shows molecular features associated with CHEK2P3 in patient tissues and cancer cell lines. In patient samples, CHEK2P3 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
